CA2317117A1 - Proteine apparentee aux ldl et son utilisation - Google Patents

Proteine apparentee aux ldl et son utilisation Download PDF

Info

Publication number
CA2317117A1
CA2317117A1 CA002317117A CA2317117A CA2317117A1 CA 2317117 A1 CA2317117 A1 CA 2317117A1 CA 002317117 A CA002317117 A CA 002317117A CA 2317117 A CA2317117 A CA 2317117A CA 2317117 A1 CA2317117 A1 CA 2317117A1
Authority
CA
Canada
Prior art keywords
polypeptide
nucleic acid
seq
amino acid
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002317117A
Other languages
English (en)
Inventor
Sean A. Mccarthy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2317117A1 publication Critical patent/CA2317117A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

L'invention concerne des molécules d'acides nucléiques isolées, dénommées TANGO 136, qui codent pour des protéines transmembranaires présentant une homologie avec les protéines membres de la famille des récepteurs des LDL; des molécules d'acides nucléiques antisens, des vecteurs d'expression recombinants contenant les molécules d'acides nucléiques de l'invention, des cellules hôtes dans lesquelles ont été introduits lesdits vecteurs d'expression et des animaux transgéniques non humains chez lesquels une molécule d'acides nucléiques de l'invention a été introduite ou invalidée; des polypeptides isolés, des polypeptides de fusion, des peptides antigéniques et des anticorps; et des méthodes de diagnostic, de criblage et de traitement faisant appel aux compositions de l'invention.
CA002317117A 1998-10-30 1999-10-27 Proteine apparentee aux ldl et son utilisation Abandoned CA2317117A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18317598A 1998-10-30 1998-10-30
US09/183,175 1998-10-30
PCT/US1999/025178 WO2000026227A1 (fr) 1998-10-30 1999-10-27 Proteine apparentee aux ldl et son utilisation

Publications (1)

Publication Number Publication Date
CA2317117A1 true CA2317117A1 (fr) 2000-05-11

Family

ID=22671749

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002317117A Abandoned CA2317117A1 (fr) 1998-10-30 1999-10-27 Proteine apparentee aux ldl et son utilisation

Country Status (5)

Country Link
EP (1) EP1051429A1 (fr)
JP (1) JP2002529053A (fr)
AU (1) AU1236600A (fr)
CA (1) CA2317117A1 (fr)
WO (1) WO2000026227A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t

Also Published As

Publication number Publication date
AU1236600A (en) 2000-05-22
EP1051429A1 (fr) 2000-11-15
JP2002529053A (ja) 2002-09-10
WO2000026227A1 (fr) 2000-05-11
WO2000026227A9 (fr) 2000-09-21

Similar Documents

Publication Publication Date Title
US8187819B2 (en) Methods of identifying compounds that bind TANGO240
AU751396B2 (en) Novel molecules of the Tango-77 related protein family and uses thereof
US6872811B1 (en) HRPCa9 and HRPCa10 nucleic acids and polypeptides
US20050032172A1 (en) Novel molecules of the FTHMA-070-related protein family and the T85-related protein family and uses thereof
WO1999054437A2 (fr) Nouvelles molecules de la famille des proteines liees a t125 et utilisations de celles-ci
US6380382B1 (en) Gene encoding a protein having diagnostic, preventive, therapeutic, and other uses
WO2000008045A2 (fr) Nouvelles molecules de la famille de proteines apparentees a tango-93 et leurs utilisations
WO2000050443A9 (fr) Proteines secretees et leurs utilisations
US20050260702A1 (en) Novel integrin alpha subunit and uses thereof
US20020025551A1 (en) Novel molecules of the t129-related protein family and uses thereof
US6485921B1 (en) UBCLP and uses thereof
CA2317117A1 (fr) Proteine apparentee aux ldl et son utilisation
US20020164330A1 (en) Novel molecules of the tango-77 related protein family and uses thereof
EP1586660A1 (fr) Nouvelles molécules de la famille des protéines liées à T85 et utilisation des dites molécules
WO2001081414A2 (fr) Nouvelle sous-unite $g(a) d'integrine et utilisations correspondantes
WO2001000644A1 (fr) Nouveaux genes codant pour des proteines s'utilisant a des fins de diagnostic, preventives, therapeutiques et autres
WO1999067415A9 (fr) Nouvelles molecules de la famille de proteines associees a t110 et leurs utilisations

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20031027